Sagar Lonial

1 month ago | tandfonline.com | Sagar Lonial |Meletios A. Dimopoulos |Jesus G Berdeja |Paul Richardson

ABSTRACTMultiple myeloma (MM) is a plasma cell neoplasm that stems from the malignant transformation of clonal plasma cells. It is characterized by multiple periods of remission and relapse requiring multiple lines of therapy, with response to treatment and survival decreasing with each successive relapse. To achieve deep and durable responses in relapsed/refractory MM (RRMM), novel treatments are required.

Jan 20, 2025 | cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman

January 20, 2025By Panelists discuss successful collaborations between academic centers and community practices in the context of (chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, key lessons learned in integrating CAR T therapy into the treatment landscape, and future plans for expanding CAR T therapy’s role in earlier lines of multiple myeloma treatment.

Jan 20, 2025 | cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman

January 20, 2025By Panelists discuss a clinical scenario involving a 56-year-old male man with myeloma and del 17p deletion, treated with RVD induction, auto transplant, and lenalidomide maintenance, who relapsed after 2 years and is now referred to discuss chimeric antigen receptor (CAR) CAR-T versus vs standard therapy, sharing key takeaways and pearls from the case.

Jan 20, 2025 | cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman

January 20, 2025By Panelists discuss their institution’s approach to co-management and co-monitoring of (chimeric antigen receptor (CAR) -T patients, strategies to facilitate seamless transitions of care between academic centers and community practices, common challenges in the CAR -T referral process and solutions, and advice for community physicians on the timing and preparation for patient referrals.

Jan 10, 2025 | cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman

January 10, 2025 By Panelists discuss which patients are considered for CAR-T therapy in second-line treatment for relapsed/refractory multiple myeloma (R/R MM) (cilta-cel vs ide-cel), describe the specific criteria and institutional guidelines used to determine patient eligibility, and explore how non-medical factors like such as location and financial considerations impact patient selection, while also outlining the typical CAR-T referral process from community physician outreach to patient...